0001193125-22-218096.txt : 20220811 0001193125-22-218096.hdr.sgml : 20220811 20220811091056 ACCESSION NUMBER: 0001193125-22-218096 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220810 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220811 DATE AS OF CHANGE: 20220811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viracta Therapeutics, Inc. CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943295878 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51531 FILM NUMBER: 221154003 BUSINESS ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 BUSINESS PHONE: 858-400-8470 MAIL ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 FORMER COMPANY: FORMER CONFORMED NAME: SUNESIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980501 8-K 1 d388911d8k.htm 8-K 8-K
false 0001061027 0001061027 2022-08-10 2022-08-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2022

 

 

VIRACTA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-51531   94-3295878

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

2533 S Coast Hwy 101, Suite 210  
Cardiff, California   92007
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 400-8470

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value   VIRX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 10, 2022, the Board of Directors (the “Board”) of Viracta Therapeutics, Inc. (the “Company”) increased the size of the Board to eleven (11) and appointed Jane Chung, RPh to the Board to fill the vacancy resulting from such increase, effective August 10, 2022. Ms. Chung will serve as a Class III director. In addition, Ms. Chung was appointed as a member of the Nominating & Governance Committee of the Board.

Jane Chung, RPh, 51, has served as the Chief Commercial Officer at Sutro Biopharma since August 2021. From May 2015 to August 2021, Ms. Chung served in several leadership roles at AstraZeneca Pharmaceuticals, including as President and General Manager of AstraZeneca Canada, Vice President of Sales and Marketing of U.S. lmmuno-Oncology, and Senior Commercial Business Director. Prior to that, from May 2013 to May 2015, Ms. Chung served as a Regional Sales Director and Director of Sales Productivity and Effectiveness for Onyx Pharmaceuticals Inc. From October 2003 to May 2013, she served in various roles for Genentech, Inc., including as Commercial Operations Manager, Division Manager and Senior Marketing Manager. Ms. Chung also serves on non-profit boards in the science, education and community development arenas. Ms. Chung received a B.S. in Pharmacy from St. John’s University and a B.A. in Psychology from Columbia University.

Ms. Chung will be compensated in accordance with the Company’s amended and restated outside director compensation policy, which has been filed as Exhibit 10.12 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 13, 2021. In addition, Ms. Chung will enter into the Company’s standard form of indemnification agreement, a copy of which has been filed as Exhibit 10.5 to the Company’s Registration Statement on Form S-1 (File No. 333-121646) filed with the SEC on December 23, 2004.

There is no arrangement or understanding between Ms. Chung and any other persons pursuant to which Ms. Chung was elected as a director. In addition, Ms. Chung is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K. There is no family relationship between Ms. Chung and any of the Company’s directors or executive officers. The Board has determined that Ms. Chung meets the applicable independence requirements of The Nasdaq Stock Market LLC.

Item 7.01. Regulation FD Disclosure.

On August 11, 2022, the Company issued a press release announcing the appointment of Ms. Chung to the Board. A copy of the press release is furnished herewith as Exhibit 99.1.

The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
Number		   

Description

99.1    Press Release, dated August 11, 2022
Exhibit 104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 11, 2022

 

/s/ Daniel Chevallard

Daniel Chevallard
Chief Operating Officer and Chief Financial Officer
 EX-99.1 2 d388911dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

PR Newswire, San Diego, August 11, 2022 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to its Board of Directors.

“Ms. Chung’s unique combination of commercial and executive experience in oncology make her an ideal fit for Viracta’s Board,” said Roger J. Pomerantz, M.D., F.A.C.P., Chairman of the Board of Directors of Viracta. “She has an impressive record of building and leading teams supporting multi-billion-dollar oncology franchises, as well as a firm understanding of how to optimize drug launches. We expect her expertise to be invaluable as we position Viracta for the next stage of its evolution through the advancement of our pivotal NAVAL-1 study in Epstein-Barr virus-positive lymphoma, and Phase 1b/2 trial in advanced EBV+ solid tumors. It is my pleasure to welcome her to the Board and I am eager to begin working together.”

Ms. Chung added, “Joining Viracta’s Board provides an exciting opportunity. The company’s lead candidate, Nana-val, has produced strong Phase 1b/2 data in EBV-positive lymphoma and has a novel mechanism of action that confers broad therapeutic and commercial potential. Both of its clinical trials are moving towards key updates expected later this year and the team leading these efforts has the requisite experience and expertise to succeed. I look forward to offering my guidance to company management as they execute on their strategic objectives.”

Ms. Chung joins Viracta’s Board with over 20 years of commercial leadership experience in the pharmaceutical and biotechnology industry, focused mostly on innovative oncology medicines and broadly across executive management, franchise leadership, marketing, sales, operations, and market access functions. She is currently the Chief Commercial Officer at Sutro Biopharma, where she has been responsible for building and leading global commercialization since August 2021. From May 2015 to August 2021, Ms. Chung served in several leadership roles at AstraZeneca Pharmaceuticals, including as President and General Manager of AstraZeneca Canada, Vice President of Sales and Marketing of U.S. lmmuno-Oncology, and Senior Commercial Business Director. Prior to that, from May 2013 to May 2015, Ms. Chung served as a Regional Sales Director and Director of Sales Productivity and Effectiveness for Onyx Pharmaceuticals Inc. From October 2003 to May 2013, she served in various commercial roles for Genentech, Inc., including as Commercial Operations Manager, Division Manager and Senior Marketing Manager.

Prior to joining industry, Ms. Chung worked as an Oncology Pharmacist at Mount Sinai Hospital and a Clinical Pharmacist at NY Presbyterian Weill Cornell Hospital in New York City. Ms. Chung also serves on non-profit boards in the science, education, and community development arenas. Ms. Chung received a B.S. in Pharmacy from St. John’s University and a B.A. in Psychology from Columbia University.

About Nana-val (Nanatinostat and Valganciclovir)

Nanatinostat is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta. Nanatinostat is selective for specific isoforms of Class I HDACs, which is key to inducing viral genes that are epigenetically silenced in Epstein-Barr virus (EBV)-associated malignancies. Nanatinostat is currently being investigated in combination with the antiviral agent valganciclovir as an all-oral combination therapy, Nana-val, in various subtypes of EBV-associated malignancies. Ongoing trials include a pivotal, global, multicenter, open-label Phase 2 basket trial in multiple subtypes of relapsed/refractory EBV+ lymphoma (NAVAL-1) as well as a multinational Phase 1b/2 trial in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.

 

Page | 1

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Forward-Looking Statements

This communication contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the details, timeline and expected progress for Viracta’s ongoing trials and updates regarding the same; and other statements that are not historical facts. Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: Viracta’s ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta’s plans to develop and commercialize its product candidates, including all oral combinations of nanatinostat and valganciclovir; the timing of initiation of Viracta’s planned clinical trials; the timing of the availability of data from Viracta’s clinical trials; previous preclinical and clinical results may not be predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Viracta’s product candidates; Viracta’s ability to manufacture or supplying nanatinostat, valganciclovir and pembrolizumab for clinical testing; Viracta’s ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to Viracta’s competitors and its industry; the impact of government laws and regulations; Viracta’s ability to protect its intellectual property position; and Viracta’s estimates regarding future expenses, capital requirements and need for additional financing in the future.

These risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in Viracta’s reports and other documents that Viracta has filed, or will file, with the SEC from time to time and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.

 

Page | 2

Investor Relations Contact:

Ashleigh Barreto

Head of Investor Relations & Corporate Communications

Viracta Therapeutics, Inc.

abarreto@viracta.com

 

SOURCE Viracta Therapeutics, Inc.

 

Page | 3

EX-101.SCH 3 virx-20220810.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 virx-20220810_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 virx-20220810_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g388911g0811005344686.jpg GRAPHIC begin 644 g388911g0811005344686.jpg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htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Aug. 10, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001061027
Document Type 8-K
Document Period End Date Aug. 10, 2022
Entity Registrant Name VIRACTA THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 000-51531
Entity Tax Identification Number 94-3295878
Entity Address, Address Line One 2533 S Coast Hwy 101
Entity Address, Address Line Two Suite 210
Entity Address, City or Town Cardiff
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92007
City Area Code (858)
Local Phone Number 400-8470
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value
Trading Symbol VIRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d388911d8k_htm.xml IDEA: XBRL DOCUMENT 0001061027 2022-08-10 2022-08-10 false 0001061027 8-K 2022-08-10 VIRACTA THERAPEUTICS, INC. DE 000-51531 94-3295878 2533 S Coast Hwy 101 Suite 210 Cardiff CA 92007 (858) 400-8470 false false false false Common Stock, $0.0001 par value VIRX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d388911d8k.htm d388911dex991.htm virx-20220810.xsd virx-20220810_lab.xml virx-20220810_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d388911d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d388911d8k.htm" ] }, "labelLink": { "local": [ "virx-20220810_lab.xml" ] }, "presentationLink": { "local": [ "virx-20220810_pre.xml" ] }, "schema": { "local": [ "virx-20220810.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "virx", "nsuri": "http://viracta.com/20220810", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d388911d8k.htm", "contextRef": "duration_2022-08-10_to_2022-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d388911d8k.htm", "contextRef": "duration_2022-08-10_to_2022-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://viracta.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-22-218096-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-218096-xbrl.zip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